Ketoconazole
- Generic Name
- Ketoconazole
- Brand Names
- Extina, Ketodan, Ketoderm, Nizoral, Xolegel, Ketoconazole HRA
- Drug Type
- Small Molecule
- Chemical Formula
- C26H28Cl2N4O4
- CAS Number
- 65277-42-1
- Unique Ingredient Identifier
- R9400W927I
- Background
Ketoconazole is an imidazole antifungal agent used in the prevention and treatment of a variety of fungal infections. It functions by preventing the synthesis of ergosterol, the fungal equivalent of cholesterol, thereby increasing membrane fluidity and preventing growth of the fungus. Ketoconazole was first approved in an oral formulation for systemic use by...
- Indication
Ketoconazole is used in the treatment or prevention of fungal infections including blastomycosis, candidiasis, coccidioidomycosis, histoplasmosis, chromomycosis, and paracoccidioidomycosis. In Europe, it is also used in the treatment of endogenous Cushing's syndrome.
- Associated Conditions
- Bacterial Vaginosis (BV), Blastomycosis, Candidiasis, Systemic, Chromoblastomycosis, Chronic Mucocutaneous Candidiasis (CMC), Coccidioidomycosis, Dandruff, Endogenous Cushing's Syndrome, Fungal Infections, Histoplasmosis, Paracoccidioidomycosis, Seborrheic Dermatitis, Tinea Corporis caused by Epidermophyton floccosumin, Tinea Corporis caused by Trichophyton mentagrophytes, Tinea Corporis caused by Trichophyton rubrum, Tinea Cruris caused by Epidermophyton floccosumin, Tinea Cruris caused by Trichophyton mentagrophytes, Tinea Cruris caused by Trichophyton rubrum, Tinea Pedis caused by Epidermophyton floccosumin, Tinea Pedis caused by Trichophyton mentagrophytes, Tinea Pedis caused by Trichophyton rubrum, Vaginal Candidiasis, Vulvovaginal Candidiasis, Cutaneous candidiasis, Recalcitrant Dermatophytosis, Tinea versicolor caused by Malassezia infection
- Associated Therapies
- -
Hormone Therapy Plus Chemotherapy as Initial Treatment for Local Failures or Advanced Prostate Cancer
- Conditions
- Interventions
- First Posted Date
- 2015-09-25
- Last Posted Date
- 2018-11-28
- Target Recruit Count
- 19
- Registration Number
- NCT02560051
- Locations
- 🇺🇸
UTHealth Memorial Hermann Cancer Center, Houston, Texas, United States
Hormonal Therapy and Chemotherapy Followed by Prostatectomy in Patients With Prostate Cancer
- Conditions
- Interventions
- First Posted Date
- 2015-07-10
- Last Posted Date
- 2018-11-27
- Target Recruit Count
- 4
- Registration Number
- NCT02494713
- Locations
- 🇺🇸
UTHealth Memorial Hermann Cancer Center, Houston, Texas, United States
Study to Investigate the Effect of Ketoconazole Mediated CYP3A4 Inhibition on Pharmacokinetics of Tamsulosin in Healthy Male Volunteers
- First Posted Date
- 2014-10-15
- Last Posted Date
- 2014-10-15
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 24
- Registration Number
- NCT02264171
Hormonal Mechanisms of Sleep Restriction
- Conditions
- Interventions
- First Posted Date
- 2014-10-06
- Last Posted Date
- 2023-11-07
- Target Recruit Count
- 40
- Registration Number
- NCT02256865
- Locations
- 🇺🇸
Los Angeles Biomedical Research Institute, Torrance, California, United States
Relative Bioavailability of Single Doses of Dabigatran Etexilate When Administered Alone or in Combination With a Single Dose of Ketoconazole or in Combination With q.d. Ketoconazole at Steady State in Healthy Male and Female Volunteers
- First Posted Date
- 2014-06-23
- Last Posted Date
- 2014-06-23
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 24
- Registration Number
- NCT02170675
Fenretinide Lym-X-Sorb + Ketoconazole + Vincristine for Recurrent or Resistant Neuroblastoma
- Conditions
- Interventions
- First Posted Date
- 2014-06-13
- Last Posted Date
- 2022-03-31
- Lead Sponsor
- South Plains Oncology Consortium
- Target Recruit Count
- 4
- Registration Number
- NCT02163356
- Locations
- 🇺🇸
Cook Children's Hospital, Fort Worth, Texas, United States
🇺🇸UT Southwestern Medical Center, Dallas, Texas, United States
🇺🇸Medical College of Wisconsin, Milwaukee, Wisconsin, United States
ITT-5 Mechanisms of Spermatogenesis in Man
- Conditions
- Interventions
- First Posted Date
- 2014-05-28
- Last Posted Date
- 2019-12-18
- Lead Sponsor
- University of Washington
- Registration Number
- NCT02147964
- Locations
- 🇺🇸
University of Washington Medical Center (Health Sciences), Seattle, Washington, United States
Expanded Access Study of Fenretinide Lym-X-Sorb Plus Ketoconazole in Neuroblastoma
- Conditions
- First Posted Date
- 2014-03-03
- Last Posted Date
- 2022-03-21
- Lead Sponsor
- South Plains Oncology Consortium
- Registration Number
- NCT02075177
- Locations
- 🇺🇸
University of Oklahoma Health Science Center, Oklahoma City, Oklahoma, United States
🇺🇸UT Southwestern Medical Center, Dallas, Texas, United States
🇺🇸Cook Children's Hospital, Fort Worth, Texas, United States
A Study to Assess the Effect of Ketoconazole on the Metabolism of ABT-199
- First Posted Date
- 2013-10-25
- Last Posted Date
- 2017-11-20
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 12
- Registration Number
- NCT01969669
- Locations
- 🇺🇸
Site Reference ID/Investigator# 97498, Tucson, Arizona, United States
🇺🇸Site Reference ID/Investigator# 92593, Lebanon, New Hampshire, United States
🇺🇸Site Reference ID/Investigator# 101415, Hackensack, New Jersey, United States
A Study to Evaluate the Relative Bioavailability, Food Effect and Effect of Ketoconazole on the Rate and Extent of Absorption of Solid Dosage Formulation(s) of JNJ-40411813
- First Posted Date
- 2013-08-30
- Last Posted Date
- 2013-09-09
- Target Recruit Count
- 36
- Registration Number
- NCT01932320
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.